Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) Head-To-Head Contrast

Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Alkermes and Structure Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0	3	9	2	2.93
Structure Therapeutics	1	0	7	1	2.89

Alkermes currently has a consensus price target of $42.00, indicating a potential upside of 35.57%. Structure Therapeutics has a consensus price target of $68.67, indicating a potential upside of 146.38%. Given Structure Therapeutics’ higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Alkermes.

Profitability

This table compares Alkermes and Structure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	23.15%	24.86%	17.14%
Structure Therapeutics	N/A	-21.31%	-20.34%

Volatility & Risk

Alkermes has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.65, indicating that its stock price is 265% less volatile than the S&P 500.

Institutional and Insider Ownership

95.2% of Alkermes shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Alkermes and Structure Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.51 billion	3.40	$367.07 million	$2.08	14.89
Structure Therapeutics	N/A	N/A	-$122.53 million	($1.05)	-26.54

Alkermes has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Alkermes beats Structure Therapeutics on 12 of the 14 factors compared between the two stocks.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.